Biocon — 360° view

Biocon, a company in the Pharmaceuticals industry, reported revenue of ₹4,389 crore and net profit of ₹57 crore for the September 2026 quarter.

Biocon (NSE: BIOCON) closed at ₹364.40 on 20 Nov 2026, down 7.8% over the past year. Its market capitalisation is ₹59,386 crore and it trades at 87.2 times earnings.

Share price
₹364.40 (20 Nov 2026)
Market cap
₹59,386 Cr (20 Nov 2026)
P/E
87.17 (20 Nov 2026)
Revenue
₹4,389 Cr (September 2026 quarter)
Net profit
₹57 Cr (September 2026 quarter)
ROCE
3.61% (FY26)
ROE
1.40% (FY26)
Book value
₹214 (FY26)
Dividend yield
0.14% (last 12 months to 20 Nov 2026)
52-week high / low
₹447.15 / ₹318.40 (20 Nov 2026)
1-year return
-7.8% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: BIOCON

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.